Clinical Trial Update: Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

View source ↗

Summary

Eli Lilly's RET inhibitor selpercatinib (Retevmo) has been approved for marketing to treat cancers driven by RET activation, including non-small cell lung cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Medullary Thyroid Carcinoma
• Non-small Cell Lung Cancer
• Pancreatic Cancer
• Papillary Thyroid Carcinoma

Drugs mentioned

• RETEVMO (selpercatinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Non Small Cell Lung Cancer, Medullary Thyroid Cancer | Status: APPROVED_FOR_MARKETING